UX111 (Ultragenyx Pharmaceutical Inc.) is an investigational single-infusion gene therapy proposed for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA).
UX111 (Ultragenyx Pharmaceutical Inc.) is an investigational single-infusion gene therapy proposed for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA).
Hayes Report Sale Policy: Hayes will review your request to purchase a report and respond to you. Individuals requesting reports due to a payment denial should contact the involved health insurer for details and information.
Please contact us if you are interested in a Hayes subscription.
Learn more about our Privacy Policy
This site uses cookies. By continuing to use this website, you agree to their use. For details, please review our Privacy Policy